These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25612644)

  • 1. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
    Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
    Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
    Shimada K; Tomita A; Saito S; Kiyoi H
    Br J Haematol; 2014 Aug; 166(3):455-7. PubMed ID: 24673649
    [No Abstract]   [Full Text] [Related]  

  • 4. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R; Kitada S; Flinn IW; Pearson M; Young D; Reed JC; Byrd JC
    J Clin Oncol; 2003 Apr; 21(8):1466-71. PubMed ID: 12697868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
    Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
    Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
    Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
    Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
    Mankaï A; Bordron A; Renaudineau Y; Martins-Carvalho C; Takahashi S; Ghedira I; Berthou C; Youinou P
    Cancer Res; 2008 Sep; 68(18):7512-9. PubMed ID: 18794139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
    Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
    Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
    J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
    Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L; Wang DS; Lehman A; Chen CS; Johnson AJ; Marcucci G; Lee RJ; Lee LJ; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2008 Dec; 112(13):5180-9. PubMed ID: 18772452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
    Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
    Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.
    D'Auria F; Guariglia R; Villani O; Mansueto G; Grieco V; Zonno A; Bianchino G; Di Giovannantonio L; Vita G; Musto P
    Clin Ther; 2010 Oct; 32(11):1911-6. PubMed ID: 21095486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.